Last reviewed · How we verify
Cartonic (amrinone)
At a glance
| Generic name | amrinone |
|---|---|
| Sponsor | Sanofi |
| Drug class | amrinone |
| Target | cGMP-inhibited 3',5'-cyclic phosphodiesterase A |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
- Decompensated cardiac failure
Common side effects
Key clinical trials
- Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow (PHASE3)
- Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage (PHASE3)
- Comparison of Milrinone and Epinephrine on TAPSE (NA)
- Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
- Milrinone in Congenital Diaphragmatic Hernia (PHASE2)
- Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation (PHASE2)
- Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
- Cardiac Power Output in Cardiogenic Shock Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cartonic CI brief — competitive landscape report
- Cartonic updates RSS · CI watch RSS
- Sanofi portfolio CI